Animal derived surfactant extract for treatment of respiratory distress syndrome
about
Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infantsSurfactant for meconium aspiration syndrome in term and late preterm infantsDelayed introduction of progressive enteral feeds to prevent necrotising enterocolitis in very low birth weight infantsSurfactant therapy for bronchiolitis in critically ill infantsAnimal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndromeAnimal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndromeComparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infantsNebulised surfactant in preterm infants with or at risk of respiratory distress syndromeSurfactant therapy for bronchiolitis in critically ill infantsProphylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infantsSurfactant for pulmonary haemorrhage in neonatesDelayed introduction of progressive enteral feeds to prevent necrotising enterocolitis in very low birth weight infantsEarly versus delayed selective surfactant treatment for neonatal respiratory distress syndromeSurfactant for bacterial pneumonia in late preterm and term infantsIntratracheal instillation of corticosteroids using surfactant as a vehicle for the prevention of chronic lung disease in preterm infants with respiratory distress syndromeLaryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndromePharyngeal instillation of surfactant before the first breath for prevention of morbidity and mortality in preterm infants at risk of respiratory distress syndromeDelayed introduction of progressive enteral feeds to prevent necrotising enterocolitis in very low birth weight infantsSurfactant therapy for bronchiolitis in critically ill infantsIntra-amniotic surfactant for women at risk of preterm birth for preventing respiratory distress in newbornsLaryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndromePharyngeal instillation of surfactant before the first breath for prevention of morbidity and mortality in preterm infants at risk of respiratory distress syndromeNebulised surfactant for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndromeProphylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infantsPathogenesis of bronchopulmonary dysplasia: when inflammation meets organ developmentPediatric Acute Respiratory Distress Syndrome: Fibrosis versus RepairThe Role of Surfactant in Lung Disease and Host Defense against Pulmonary InfectionsComparative study of clinical pulmonary surfactants using atomic force microscopySurfactant therapy for acute lung injury and acute respiratory distress syndrome.A systematic review of randomized controlled trials for the prevention of bronchopulmonary dysplasia in infants.In vivo effect of pneumonia on surfactant disaturated-phosphatidylcholine kinetics in newborn infantsPoractant alfa versus bovine lipid extract surfactant for infants 24+0 to 31+6 weeks gestational age: A randomized controlled trial.Impact of changes in perinatal care on neonatal respiratory outcome and survival of preterm newborns: an overview of 15 years.Efficacy and safety of surfactant replacement therapy for preterm neonates with respiratory distress syndrome in low- and middle-income countries: a systematic review.Prevention and management of bronchopulmonary dysplasia: Lessons learned from the neonatal research network.Bronchopulmonary Dysplasia: Chronic Lung Disease of Infancy and Long-Term Pulmonary Outcomes.The Efficacy of Surfactant Replacement Therapy in the Growth-Restricted Preterm Infant: What is the Evidence?Evidence Based Medicine Series: Part 4. Why Some Good Studies with Clinically Important Results Cannot be Applied to Our Patients.A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome.Saving Newborn Babies - The Benefits of Interventions in Neonatal Care in Norway over More Than 40 Years.
P2860
Q24187014-90231D78-315F-4D47-8B93-583A8985906CQ24187318-A00A5D8B-4CDE-4660-AB52-41583D609BBFQ24187497-698B78EC-ED50-4542-8C3C-5B10BB4571D7Q24187760-4E8020F3-3D69-4CFF-8124-C6827DC72240Q24187777-D4EFB67B-984B-4204-809F-ECF09AC3980BQ24187839-A411F04E-36E2-4AD1-B3ED-B77C9B9D5C92Q24197942-F76577B4-5D23-4A18-8DCB-58654C74D39BQ24198153-2198A35C-EEEA-440D-A805-5FA485905948Q24200647-EC849309-AA27-42D0-A89D-8D4D5DA9DC94Q24201075-73A02970-1317-4281-AD79-C2D358BE6809Q24201963-E3ECA54B-70B1-491C-9E41-C86F958CD168Q24202657-645383F8-9B4A-41C9-8136-80D2DA3A68CAQ24202890-203B3F26-2CCB-41BF-9F02-767E152DED70Q24203694-18BF1714-20B1-4549-8AB8-6CD77F196B79Q24235457-AC067980-583D-44C0-A996-20C31654993BQ24235572-2F4916B0-ED12-4DE8-B750-B9B83E7D403DQ24235658-9C543ADA-5B6F-46DB-9A56-A0B0C9B88EFCQ24235703-D5DD3297-339E-4E51-9958-42F17E341249Q24236066-39D2A5E1-EA9B-4ACA-9491-6B3D51C3E8DEQ24240793-42B24012-1FB9-44F7-9076-E1FDFAE05938Q24241523-68926D6D-E42C-435D-8A48-77B8E75E6736Q24241537-6F2DCA90-B37D-42A1-8839-37F573142120Q24241781-31B407E2-B912-4A07-994E-0DE075908944Q26471476-0BBB6B38-AF40-4D81-849A-ABAE77F298CFQ26746072-35F607A0-0C98-45EE-9B3B-375165506FEBQ26749366-45240705-ECF7-42E6-BAA8-400E9693A1C4Q26865690-93A7CE3A-DB76-4BD7-B4D3-9DD37C5BF043Q28833705-BE253B15-05BD-4DCB-BDCD-4A40894E6D34Q30426177-23C108C6-377E-4822-90F2-1AAE4BD1AFDFQ34123512-DAE5BD32-3E34-46B2-926B-DBA0BB10AB48Q34796387-0DBFD415-D52E-4427-B428-3D347E8DDC0EQ36362972-BAADE028-0FFF-493C-B737-2B3E2CCFEC36Q36516093-A02693C1-1D54-4F7C-84F3-5E9F0BFFBEDFQ36846504-DE3CF594-E1E6-40FE-A0FE-A1D18F2019E7Q37613608-E8D8DC98-CF5F-4552-97B2-151414B76254Q37628175-9F71A8D8-BF7D-4443-B823-4D19EA90F4C7Q38268677-89F25A81-1155-4B11-BB21-3F79A75A10FDQ38326438-C161DD21-CDFC-4972-9C2D-8D7D47409BC0Q38808065-D0839FDB-C557-4105-A19B-6A5D73ACE8CBQ40026944-1D8A153A-F906-48DF-A348-3AC7017ACE78
P2860
Animal derived surfactant extract for treatment of respiratory distress syndrome
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Animal derived surfactant extract for treatment of respiratory distress syndrome
@ast
Animal derived surfactant extract for treatment of respiratory distress syndrome
@en
Animal derived surfactant extract for treatment of respiratory distress syndrome
@en-gb
Animal derived surfactant extract for treatment of respiratory distress syndrome
@nl
type
label
Animal derived surfactant extract for treatment of respiratory distress syndrome
@ast
Animal derived surfactant extract for treatment of respiratory distress syndrome
@en
Animal derived surfactant extract for treatment of respiratory distress syndrome
@en-gb
Animal derived surfactant extract for treatment of respiratory distress syndrome
@nl
prefLabel
Animal derived surfactant extract for treatment of respiratory distress syndrome
@ast
Animal derived surfactant extract for treatment of respiratory distress syndrome
@en
Animal derived surfactant extract for treatment of respiratory distress syndrome
@en-gb
Animal derived surfactant extract for treatment of respiratory distress syndrome
@nl
P2860
P3181
P1476
Animal derived surfactant extract for treatment of respiratory distress syndrome
@en
P2093
Nadine Seger
P2860
P3181
P356
10.1002/14651858.CD007836
P50
P577
2009-04-15T00:00:00Z